13F Portfolios

Gray Foundation: NEUROCRINE BIOSCIENCES INC (NBIX): Quarterly 13F Position History

As of Q2 2026, Gray Foundation reported 37,800 shares of NEUROCRINE BIOSCIENCES INC (NBIX), worth $6.4M and representing 1.4% of its 13F equity book. The position first appeared in Q4 2025 and has been disclosed across 3 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q2 2026 37,800 0 $6.4M 1.4% $168.5
Q1 2026 37,800 0 $5.0M 1.3% $131.7
Q4 2025 37,800 $5.4M 1.3% $141.8

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.

When did Gray Foundation first disclose a NBIX position in 13F-HR filings?

Gray Foundation first reported NEUROCRINE BIOSCIENCES INC (NBIX) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.

What was Gray Foundation's most recent quarter-over-quarter share-count change in NBIX?

Gray Foundation held the same 37,800 shares of NBIX between Q1 2026 and Q2 2026, so the reported share count was unchanged quarter-over-quarter.

Does the implied price-per-share represent Gray Foundation's cost basis in NBIX?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.